Cannabis Culture
Cannabis Culture
D.C. mayor expands cannabis protections for workers

D.C. mayor expands cannabis protections for workers
Mayor Muriel Bowser signed an order last week clarifying legal protections for certain District employees who consume cannabis while away from the job. The new rules apply to all District government agencies under the direct administrative authority of the mayor.
Under the rules, many would-be employees will no longer face pre-employment drug screenings. The order states: “Employees who are not in a safety-sensitive position will be tested for drugs only upon reasonable suspicion, or after an accident or incident. Thus, those employees not in safety-sensitive positions may find that they can use cannabis, with or without a medical card authorizing [it], so long as they are not impaired at work.”
Commenting on the policy change, NORML NE Political Associate Tyler McFadden said: “Employment protections are critical to ensure that law-abiding adults are not unduly discriminated against in their efforts to be productive members of society solely because of their use of cannabis while off the job. This order provides clarity and guidance to employers and peace of mind to the employees who work in the District of Columbia.”
For employees seeking safety-sensitive positions, the order states that those who test positive for the presence of cannabis on a pre-employment drug screen may be “disqualified.” In some cases, however, the order states that those who initially test positive for cannabis may receive a “second opportunity to take a drug test at least two weeks after the initial test results have been provided.”
In cases involving post-accident testing, a positive drug test result for cannabis metabolites will continue to be viewed as presumptive evidence of impairment. However, this “presumption may be overcome if the employee presents clear or convincing evidence that he or she was not impaired at the time of the test.”
Because THC’s primary metabolite, carboxy-THC is lipid soluble, residual levels of the compound may persist in urine for weeks or even months post-abstinence. According to the US Department of Justice, a positive urine test screen for drug metabolites “does not indicate abuse or addiction, recency, frequency, or amount of use; or impairment.”
Earlier this month, members of the DC City Council approved Act Number A23-0114: The Medical Marijuana Program Patient Employment Protection Temporary Amendment Act, which seeks to impose explicit protections for medical cannabis patients against workplace discrimination.
Utah officials revise medical cannabis law
SALT LAKE CITY — Members of the Utah House and Senate unanimously approved legislation revising the state’s nascent medical cannabis access program during a special legislative session last week.
Under the revised plan, the distribution of medical cannabis products will no longer be overseen by public health regulators. Rather, the state will license as many as 14 private entities throughout the state to dispense cannabis products to authorized patients. The new legislation also permits courier services to engage in cannabis deliveries to those patients who either reside a significant distance from an operating dispensary or who are homebound.
Republican Gov. Gary Herbert expressed support for the changes, stating, “The bill will help provide safe and efficient access to an important medical option for patients while also taking public safety into consideration.”
This is the second time in less than a year that lawmakers have convened a special session to amend the state’s medical cannabis law. Voters in 2018 approved Proposition 2, which legalized the use and dispensing of medical cannabis to qualified patients. Shortly thereafter, lawmakers held a special legislative session where they voted to repeal and replace the initiative law with their own legislation. Specifically, lawmakers eliminated patients’ option to home cultivate cannabis, narrowed the list of qualifying conditions, and placed additional restrictions on the dispensing of cannabis products, among other changes.
Regulators want to amend rules for clinical cannabis testing
The Director of the U.S. National Institutes of Health and the Acting Commissioner of the Food and Drug Administration have acknowledged that existing federal regulations hinder clinical cannabis research, and are suggesting that scientists be able to legally access cannabis products from sources other than the University of Mississippi – the only federally licensed supply source of marijuana for research purposes.
In a letter to Sen. Brian Schatz (D-Hawaii), first obtained by Politico, the officials acknowledge that the existing monopoly on federally authorized cannabis production limits “the diversity of [cannabis] products and formulations available to researchers, [thus] slowing the development of cannabis-based medications.” The letter’s authors suggest both “licensing additional entities to supply cannabis,” as well as “enabling researchers holding Schedule I licenses for marijuana to obtain products from state authorized dispensaries.”
They conclude that the current regulations governing the clinical study of cannabis, along with the Schedule I status of marijuana under federal law, create “significant administrative cost challenges that slow this research and may deter scientists from pursuing cannabis research altogether.”
Since 2016, officials at the DEA have promised to license additional, private producers of research-grade cannabis. As of yet however, the DEA has failed to take action on more than 30 applications pending before it, and the agency has yet to provide a timeline as to when they intend to do so.
Cannabis Culture news in the Blade is provided in partnership with NORML. For more information, visit norml.org.
Cannabis Culture
LGBTQ people, weed, and mental health: what you need to know
Community uses marijuana at much higher rates than general population
Uncloseted Media published this story on May 7.
By SPENCER MACNAUGHTON | In 2025, the global cannabis market size was valued at nearly $103 billion. By 2034, that number is expected to explode by roughly 1,400 percent to more than $1.43 trillion.
In short, as an increasing number of countries legalize marijuana use, everyone is starting to consume a lot more weed. And LGBTQ people tend to use cannabis at much higher rates than the general population. One study found that 55 percent of lesbian and 45 percent of gay young adults use marijuana, compared to about 33 percent and 37 percent, respectively, of their straight counterparts.
As LGBTQ people face a mental health crisis, the mainstream stereotypes that depict weed as an antidote for anxiety, panic and depression aren’t painting the full picture. And that could be exacerbating the mental health struggles so many queer people, and especially youth, face.
Here’s what the research demonstrates about marijuana and its effects on mental health:
- Multiple studies suggest a link between marijuana use and an increased risk of mental health disorders, including schizophrenia, depression and anxiety in individuals who are genetically predisposed.
- One study found that daily marijuana use, especially among younger people, makes some individuals seven times more likely to develop psychosis.
The increase in higher-potency strains of marijuana could pose unknown risks. In 1995, the average content of Tetrahydrocannabinol (THC) in confiscated marijuana was less than 4 percent. In 2022, it was more than 16 percent. Researchers don’t know the full extent of the impact that these higher concentrations can have on mental health and especially on younger people whose brains are still developing.
- A systematic review of studies published between 2013 and 2025 found damning results for the mental health of young cannabis users:
They were 51 percent more likely to experience depression, 58 percent more likely to experience anxiety, between 50 and 65 percent more likely to experience suicidal ideation and 80 to 87 percent more likely to have attempted suicide.
- While the above stats paint a grim picture, there is also some research that suggests benefits of cannabis use:
- A 2025 systematic review found that “medicinal” weed showed some efficacy in relieving withdrawal symptoms of opioid use disorder. THC use has been associated with improvement of post-traumatic stress disorder symptoms, bipolar symptoms and sleep quality.
- Other studies found that THC administered in a controlled setting was associated with a decrease of symptoms and adverse effects for a range of mental health disorders, including schizophrenia, psychotic symptoms, and anorexia nervosa.
Beyond what we pulled from academia, there is an astounding lack of information about the interplay between weed and mental health. As we dive deeper into Mental Health Awareness Month, I hope advocacy organizations, influencers and news outlets ramp up their coverage of this important topic that affects the countless LGBTQ weed smokers, many of whom are already struggling.
Democratic Gov. Michelle Lujan Grisham earlier this month signed two separate measures into law amending the state’s marijuana policies. The first measure (House Bill 2) legalizes and regulates marijuana possession, production, and sales for adults. The second measure (Senate Bill 2) facilitates the automatic review and expungement of the records of those convicted of low-level marijuana offenses.
Lawmakers approved both bills during a special legislative session demanded by Gov. Lujan Grisham, who had been a vocal proponent of the reforms.
NORML State Policies Manager Carly Wolf said: “This is a day to celebrate! New Mexico will greatly benefit from this new revenue stream and the creation of thousands of jobs. Most notably though, legalization will spare thousands of otherwise law-abiding residents from arrest and a criminal record, and the state’s new expungement law will help provide relief to many who are suffering from the stigma and other collateral consequences associated with a prior marijuana conviction.”
The adult-use measure (House Bill 2) permits those ages 21 and older to legally purchase up to two ounces of marijuana and/or up to 16 grams of cannabis extract from licensed retailers. It also permits adults to home-cultivate up to six mature plants for their own personal use. Retail sales would begin by April 2022.
The expungement measure (Senate Bill 2) stipulates that those with past convictions for offenses made legal under this act are eligible for automatic expungement of their records. Those currently incarcerated for such offenses are eligible for a dismissal of their sentence. It’s estimated that over 150,000 New Mexico residents are eligible for automatic expungement under this measure, according to the Department of Public Safety.
Cannabis Culture news in the Blade is provided in partnership with NORML. Visit norml.org for more information.
Cannabis Culture
Delaware cannabis activists take on corporate marijuana
Criticism from medical marijuana operators claimed that HB150 offers too many cultivation and retail licenses
As the country moves forward with sweeping changes in cannabis policy reform, locals in Delaware are tangling with corporate, multi-state medical marijuana permit holders to pass a bill for full legalization.
Adult-use activists and registered medical patients were stunned to hear opposing testimony from Delaware’s medical marijuana operators. Patients already deal with limited access and costly products. Now, many see the established industry voicing opposition as simply obstructing the progress of adult-use legislation. In response, some patients are now staging a boycott of the regulated dispensaries.
During the first committee hearing for HB150, Delaware’s adult-use bill, four of the state’s six currently licensed, multi-million dollar medical cannabis facilities offered negative testimony.
Zoë Patchell, executive director of Delaware CAN responded: “This market belongs to the long-time consumers, patients, and activists. We create the demand, we’ve been the ones driving the reform efforts, and we pay the prices at dispensaries. Cannabis is more than a market – cannabis is a community. These companies cannot reasonably fathom that we are going to purchase cannabis from any entity that has proven to put profits over patients. And now they seem willing to put consumers’ lives and freedom at risk just to hold out for an unfair advantage in the industry.”
These included publicly traded Columbia Care, “Fresh Delaware” aka CCRI, CannTech Research Inc., and the owner of EZY Venture aka “The Farm.”
They all went on record condemning HB150, and pushing a false narrative about oversupply. The core demand from the permit cartel was some protection for their private business interests with guaranteed adult-use licenses.
Criticism from the medical marijuana operators claimed that HB150 offers too many new cultivation and retail licenses, underlined by deep yet unfounded fears that the new competition would put their companies out of business.
Patchell noted, “We are not going to sit back while multi-state corporate entities, that already monopolize East Coast medical markets, work to undermine our social equity and micro-license provisions.”
Cannabis Culture news in the Blade is provided in partnership with NORML. Visit norml.org for more information.
-
United Kingdom4 days agoUK government makes trans-inclusive conversion therapy ban a legislative priority
-
Federal Government4 days agoBureau of Prisons declines to reconsider transgender inmate policy
-
a&e features4 days agoYes, chef!
-
Rehoboth Beach4 days agoWhat’s new in Rehoboth Beach for summer 2026
